pharma · Breast Cancer · Prostate Cancer · UTHR
United Therapeutics Europe Ltd
United Therapeutics is a pharma organization headquartered in Silver Spring, USA. It trades on NYSE under ticker UTHR. Primary therapeutic focus areas include Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertensi
Phase 2 · mab · Ganglioneuroblastoma
Dinutuximab (UNITUXIN) is a monoclonal antibody developed by United Therapeutics Europe Ltd for the treatment of ganglioneuroblastoma, a rare neural crest-derived tumor. The drug is administered intravenously and functions as an antineoplastic and immunomodulating agent. The program, identified by internal code NCI-201
Internal code NCI-2012-03125
Dinutuximab (UNITUXIN) is a monoclonal antibody developed by United Therapeutics Europe Ltd for the treatment of ganglioneuroblastoma, a rare neural crest-derived tumor. The drug is administered intravenously and functions as an antineoplastic and immunomodulating agent. The program, identified by internal code NCI-2012-03125, completed Phase 2 clinical development with the latest milestone recorded on 24 October 2022.
Dinutuximab achieved FDA approval in the United States under BLA application number BLA125516. However, the European Medicines Agency (EMA) approved the drug on 20 March 2017 under EMEA/H/C/002800, but this authorization was subsequently withdrawn. The regulatory divergence between US approval and EMA withdrawal reflects differing benefit-risk assessments in these markets for this rare pediatric indication.
The program's completion of Phase 2 development and the historical EMA approval indicate that United Therapeutics pursued a focused development strategy in a rare disease area. The withdrawal of the EMA authorization suggests potential commercial or safety-efficacy considerations that led to market exit in Europe, while the maintained US approval indicates continued regulatory confidence in that jurisdiction.
Ganglioneuroblastoma is a rare pediatric malignancy arising from neural crest cells, representing a significant unmet medical need due to limited treatment options and poor prognosis in advanced disease. The rarity of this indication means that therapeutic options remain extremely limited, and any approved agent addresses a critical gap in pediatric oncology.
Dinutuximab's development as a monoclonal antibody targeting this indication reflects the growing recognition of immunotherapy approaches in rare pediatric cancers. The drug's US approval provides a regulatory-validated treatment option for patients with ganglioneuroblastoma, though the EMA withdrawal suggests that European regulators may have identified safety or efficacy concerns that outweighed benefits in that market.
From a commercial perspective, the rare disease designation limits the addressable patient population significantly, constraining peak sales potential. However, the orphan disease status typically provides regulatory incentives including extended exclusivity periods. The divergent regulatory outcomes—US approval versus EMA withdrawal—indicate that market access remains geographically restricted, affecting United Therapeutics' commercial strategy and patient access globally.
Competitive positioning in rare pediatric oncology is sparse, with most approved agents targeting more common malignancies. Dinutuximab's approval status in the US provides a differentiated position, though the EMA withdrawal limits European market penetration and suggests that alternative or competing approaches may be preferred in that jurisdiction.
Drug Class: Antineoplastic and immunomodulating agent (ATC L01)
Modality: Monoclonal antibody (mAb)
Route of Administration: Intravenous
Brand Name: UNITUXIN
International Nonproprietary Name (INN): Dinutuximab
Mechanism of Action: Not yet disclosed in available regulatory documentation
Molecular Target: Not yet disclosed in available regulatory documentation
Related Therapies: Other monoclonal antibodies and immunomodulating agents in pediatric oncology; specific mechanistic comparators not disclosed
First Approval: United States FDA approval under BLA125516; European EMA approval on 20 March 2017 (subsequently withdrawn)
Patent Status: Not yet disclosed
Also known as: ganglioneuroblastoma (disease), ganglioneuroblastoma (morphologic abnormality), ganglioneuroblastoma, malignant
Prevalence: Point prevalence: <1 / 1 000 000 (Worldwide) — source: Orphanet, validated.
A neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume. There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular.
ClinicalTrials.gov lists 16 registered studies for Ganglioneuroblastoma (AACT aggregate).
Phase breakdown: NA (4), PHASE3 (4), PHASE1 (3), PHASE2 (3), EARLY_PHASE1 (1), PHASE1/PHASE2 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005035), Orphanet — ganglioneuroblastoma, NCT00904241, NCT01175356, NCT01767194, NCT01798004, NCT02112617, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 completion
Phase 2 clinical development completed; latest program milestone recorded.
EMA approval
European Medicines Agency approved dinutuximab under EMEA/H/C/002800.
FDA approval
United States FDA approved dinutuximab under BLA125516; specific approval date not disclosed.
EMA withdrawal
European authorization for UNITUXIN was withdrawn; specific withdrawal date not disclosed.
The competitive landscape for ganglioneuroblastoma treatment is sparse, with limited approved agents specifically targeting this rare indication. The facts provided identify multiple approved oncology and hematology agents including AFINITOR (everolimus, Novartis), INLYTA (axitinib, Pfizer), IMBRUVICA (ibrutinib, Janssen-Cilag), KYPROLIS (carfilzomib, Amgen), VYXEOS LIPOSOMAL (daunorubicin/cytarabine, Jazz Pharmaceuticals), EVOLTRA (clofarabine, Amneal Pharma), and OFEV (nintedanib, Boehringer Ingelheim), along with chemotherapy agents including PACLITAXEL ACCORD and LYNOZYFIC (linezolid, Regeneron). However, these agents are not specifically indicated for ganglioneuroblastoma and represent broader oncology/hematology portfolios rather than direct competitors in this rare pediatric indication.
Dinutuximab's positioning as an approved monoclonal antibody in the US market provides differentiation in a therapeutically underserved space. The EMA withdrawal, however, indicates that European regulators did not maintain approval, suggesting that competing approaches or alternative treatment paradigms may be preferred in that jurisdiction. The rarity of ganglioneuroblastoma means that true head-to-head competitive data is limited, and market segmentation is driven more by regulatory access and clinical trial availability than by direct therapeutic competition.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PFIZER AUSTRALIA PTY LTD | Pfizer Australia Pty Ltd | — | approved |
| ARX-IMATINIB | Alphapharm Pty Ltd | — | approved |
| AFINITOR | Novartis Pharmaceuticals | — | approved |
| LYSODREN | S.A. | — | approved |
| INLYTA | Pfizer Australia Pty Ltd | — | approved |
| IMBRUVICA | Janssen-Cilag Pty Ltd | — | approved |
| VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS) | Jazz Pharmaceuticals Ireland Limited | — | approved |
| KYPROLIS | Amgen | — | approved |
| OFEV | Boehringer Ingelheim Pty Ltd | — | approved |
| PACLITAXEL ACCORD | Accord Healthcare Pty. | — | approved |
| LYNOZYFIC | Regeneron UK Limited | — | approved |
| EVOLTRA | Amneal Pharma Europe Ltd | — | approved |
| VINCRISTINE SULFATE | — | Tubulin inhibitor | Phase 3 |
| VINCRISTINE | — | Tubulin inhibitor | Phase 3 |
| TOPOTECAN HYDROCHLORIDE | — | DNA topoisomerase I, mitochondrial inhibitor | Phase 3 |
| TOPOTECAN | — | DNA topoisomerase I, mitochondrial inhibitor | Phase 3 |
| SARGRAMOSTIM | — | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 3 |
| LORLATINIB | — | EML4-ALK inhibitor | Phase 3 |
| ISOTRETINOIN | — | Retinoic acid receptor agonist | Phase 3 |
| IRINOTECAN | — | DNA topoisomerase I inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Dinutuximab is approved under BLA application number BLA125516. The specific approval date is not yet disclosed in the available facts.
European Union (EMA): Dinutuximab received EMA approval on 20 March 2017 under EMEA/H/C/002800, with United Therapeutics Europe Ltd listed as the Marketing Authorization Holder (MAH). This authorization was subsequently withdrawn; the specific withdrawal date and rationale are not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Orphan Designation: Status not yet disclosed, though the rare indication (ganglioneuroblastoma) suggests potential orphan drug designation in applicable jurisdictions.
Regulatory Summary: Dinutuximab demonstrates divergent regulatory outcomes across major markets, with maintained US approval contrasting with EMA withdrawal. This geographic divergence in regulatory status significantly impacts market access and commercial strategy.
Dinutuximab (UNITUXIN) is used for the treatment of ganglioneuroblastoma, a rare neural crest-derived pediatric malignancy. It is approved in the United States but is not currently approved in the European Union, as the EMA authorization was withdrawn.
Yes, dinutuximab is approved by the United States FDA under BLA application number BLA125516. The specific approval date is not yet disclosed in available regulatory documentation.
Dinutuximab received EMA approval on 20 March 2017 under EMEA/H/C/002800, but this authorization was subsequently withdrawn. It is not currently approved in the European Union.
Dinutuximab is manufactured and developed by United Therapeutics Europe Ltd, which holds the marketing authorization in jurisdictions where the drug is approved.
Dinutuximab is a monoclonal antibody (mAb) classified as an antineoplastic and immunomodulating agent. It is administered intravenously.
Dinutuximab is administered by intravenous infusion. The specific dosing schedule and administration details are not yet disclosed in available documentation.
The specific mechanism of action of dinutuximab is not yet disclosed in available regulatory or clinical documentation.
The specific molecular target of dinutuximab is not yet disclosed in available regulatory or clinical documentation.
Dinutuximab development included the Phase 2 trial NCT01767194. Specific trial design, results, and endpoints are not yet disclosed in available documentation.
Dinutuximab has completed Phase 2 clinical development as of 24 October 2022. The program is not currently in active clinical development, though it maintains FDA approval in the United States.
The specific reasons for the EMA withdrawal of dinutuximab are not yet disclosed. The withdrawal may reflect commercial considerations, safety-efficacy assessments, or other regulatory factors.
Ganglioneuroblastoma is a rare pediatric malignancy arising from neural crest cells. It represents a significant unmet medical need due to limited treatment options and poor prognosis in advanced disease.
Regulatory status of dinutuximab in Japan (PMDA) and China (NMPA) is not yet disclosed in available documentation.
Orphan drug designation status for dinutuximab is not yet disclosed, though the rare indication suggests potential eligibility in applicable jurisdictions.
The competitive landscape for ganglioneuroblastoma treatment is sparse. Dinutuximab's US approval provides a differentiated position, though broader oncology agents like AFINITOR, INLYTA, and IMBRUVICA may be used off-label in related indications.
The brand name of dinutuximab is UNITUXIN, marketed by United Therapeutics Europe Ltd in approved jurisdictions.
Dinutuximab → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: United Therapeutics' development of dinutuximab in ganglioneuroblastoma reflects a focused strategy in rare pediatric oncology. The completion of Phase 2 development and subsequent regulatory approvals indicate a commitment to addressing unmet needs in this therapeutically sparse indication. However, the EMA withdrawal suggests that the European market may not have provided sufficient commercial opportunity or that safety-efficacy considerations prompted market exit.
Competitive Implications: The sparse competitive landscape in ganglioneuroblastoma treatment means that dinutuximab's US approval provides a differentiated market position. The absence of direct competitors in this indication limits competitive pressure but also reflects the limited commercial opportunity in such a rare disease. The EMA withdrawal removes European market access, concentrating commercial focus on the US market and potentially limiting global revenue potential.
Future Catalysts: Potential future developments may include label expansions to related neural crest-derived tumors, additional clinical trial data supporting efficacy in specific patient subpopulations, or regulatory actions in undisclosed jurisdictions (Japan, China). The current Phase 2 completion status suggests that further clinical development may be limited unless new indications or patient populations are identified.
Expected Milestones: No future milestones are currently disclosed. The program's completion of Phase 2 development and the historical regulatory approvals suggest that active development may have concluded, with current focus likely on commercialization and post-marketing surveillance in the US market.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.